Voloridge Investment Management
BCTX

Voloridge Investment Management’s Briacell Therapeutics BCTX Stock Holding History

Voloridge Investment Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-101
Closed -$154K – 1425
2022
Q1 		$154K Sell
101
-1,255
-93% -$1.48M ﹤0.01% 1308
2021
Q4 		$1.68M Buy
1,356
+310
+30% +$406K 0.01% 1126
2021
Q3 		$1.27M Buy
+1,046
New +$962K 0.01% 1205

Other funds holding BCTX

KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.42% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Voloridge Investment Management's BCTX Position: Q2 2022 in Review

Voloridge Investment Management sold out of Briacell Therapeutics (BCTX) in Q2 2022, closing a stake of 101 shares — an estimated $154K sold.

Voloridge Investment Management first reported a position in BCTX in Q3 2021 and held it in 3 quarters. The position peaked at $1.68M in Q4 2021. 20 funds tracked by Wall St. Rank hold BCTX as of Q2 2022.

  • Voloridge Investment Management reported no remaining Briacell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 101 Briacell Therapeutics shares in Q2 2022, an estimated $154K.
  • Voloridge Investment Management first reported a position in Briacell Therapeutics in Q3 2021 and held it in 3 quarters.
  • Voloridge Investment Management's Briacell Therapeutics position peaked at $1.68M in Q4 2021.
  • 20 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2022.

Based on Voloridge Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.